First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
SYM Liu, HY Tu, XW Wei, HH Yan, XR Dong, JW Cui… - Nature Medicine, 2023 - nature.com
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC)
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
SYM Liu, HY Tu, XW Wei, HH Yan… - Nature …, 2023 - pubmed.ncbi.nlm.nih.gov
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC)
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
SM Liu, HY Tu, XW Wei, HH Yan, XR Dong… - Nature …, 2023 - europepmc.org
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC)
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …